Tacrolimus Response

Official Analytics partner

https://genepowerx.com/wp-content/uploads/2021/10/sloan-logo-320x228.png

Memorial Sloan kettering Cancer Hospital (Developed the first FDA approved Cancer Companion Diagnostic Test)

GenePower Cancer Companion

GenePower Cancer Companion uses targeted genomic sequencing and analysis to provide the physician with information on-

Druggable mutations in your patient for which targeted therapies are available.
Clinical trial match connector
Microsatellite Instabilty status (MSI)
Tumor Mutational Burden status (TMB)
Sample required- FFPE tissue sample
TAT(Turn Around Time)- 3- 4 weeks

Memorial Sloan Kettering Cancer Center

The world’s oldest and largest private cancer center, and GenePower(by K&H), partnered into collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors along with K&H proprietary database to provide accurate recommendations for Indian population .

Testing steps

Next gen sequencing using Illumina NovaSeq sequencer
In house developed Bioinformatics algorithms for data analysis
Final report generation using Databases in association with MSK Cancer hospital

Highlights

Over 5600 genomic alterations covered-We report substitutions, insertions, deletions, CNV, select rearrangements (Confirmed by Transcriptome) as well as genomic signatures including microsatellite instability and tumor mutation burden.
We are the only company in Genomics space lead by physicians in India.
Open Discussion channel between Oncologist, Pathologist and genomic specialist physician will lead to best treatment choices for the patient.
Simplified reports without ambiguous reporting is possible because we know exactly what a treating physician is looking for in the report.